Manulife Financial (MFC.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Manulife Financial (MFC.TO)

61.42

+1.50 (2.50%)

as of Sep 3, 2026, 8:00:00 pm Market Open.

1632 watching

Investor Insights

Sep 3, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has garnered a mixture of opinions from analysts following its recent quarterly report, which showcased positive developments despite facing challenges such as a new tax on its products for mainland Chinese residents. The company is noted for its strong presence in Asia and steady growth in its wealth management segment, which remains a highlight in its long-term strategy. However, some experts express caution, labeling MFC as a bit overvalued relative to its earnings growth potential, currently trading over 2x book value. The financial landscape for insurers in Canada appears competitive, with both MFC and its peers like TD exhibiting relatively robust performance, yet the consensus leans toward a cautious approach due to market conditions. Overall, while MFC benefits from high dividends and solid asset management, uncertainties related to its exposure to market fluctuations warrant careful monitoring for potential entry points.

Consensus

Cautious

Valuation

Fair Value

Similar

SLF

TOP PICK

Pays a nice dividend. FMV is way above the current price, 167% higher. Good Balance sheet. Book value is in an uptrend. PB is very cheap. $26.50 is resistance, so watch that, but it has busted past that before. If so, it should reach $31-32. Are expanding international. Growing earnings. What's not to like. (Analysts’ price target is $29.91)

HOLD

The lifecos have done well this year, especially Sun-Life. Both offer relative safety and growth in Asia, especially MFC. Manulife isn't a tax-loss selling candidate.

COMMENT

He’s not sure about the next few months. Long term, they have growth potential in Asia. Interest rate is a bigger issue with insurance companies. The near term performance is closely related to interest rates so it depends how you think rates will go.

PAST TOP PICK

(A Top Pick Jan 15/19, Up 30%) He is not building more on it at these levels. You have a new management team who are quietly cleaning up the problems of the previous management. They are also doing some things to push the business forward on a long term basis. It's about time people started to own it.

HOLD

Canadian insurers have been the winners this year. Volatile for a while, but the stock has rallied. Growing by mid-single digit EPS, 13-14% ROE, growing dividend, trading at 1.1x book value. Just hold it for the dividend and ride it. No more catalysts this year, but it will eventually get into the 30s. (Analysts’ price target is $29.54)

BUY

Take profits now? An income stock. Lifecos have done well this year, even though rates are low. MFC reported earnings last week and saw good growth in Asia. Their long-term growth prospects are positive. A long-term hold.

BUY

This would be the best of the life insurers. They have the cheapest valuation, the least leverage and the most opportunity for selling off legacy assets that are holding it back. It is a short term buy.

COMMENT

He used to own Manulife going into the financial crisis and have not looked at it since. It is pale in comparison to Sun Life.

HOLD

Selling insurance plus investments. Core business is doing well. Low interest rates are bad for them, but rates are not going lower. Don't rush out to sell. Good growth in core business. Good valuation. Growth in Asia.

HOLD

He almost picked MFC as a top pick, but it is moving to $25, so he chose another financial. Good earnings growth, mostly Asian. It will benefit from higher interest rates, so low rates prevent it from rising to $30. They will likely raise their dividend, so you can hold this for that dividend.

HOLD

Likes the name. Long-term, overseas operations will benefit the stock price. Insurers are doing better. Up 26% in last 12 months. Nice healthy dividend of 4.1%. (Analysts’ price target is $28.38)

BUY

MFC vs. Arc Arc is riskier while MFC is steadier. MFC is at an excellent price now, close to book value and offers a 12% ROE. Best in this sector with great Asian growth potential. They have a long way to sort out problems with long-term care in the U.S. Arc is good if you want more torque in your portfolio.

COMMENT

$35.19 is his model price, 46% upside. MFC has never gotten any respect, but he watches it. SunLife has better metrics. There's a lot of value in MFC, but financials as a whole are risky now. MFC is stuck in purgatory. Sell if it breaks below $22.60. He owns a little of this. He hasn't made up his mind about MFC.

PAST TOP PICK

(A Top Pick Oct 24/18, Up 22%) There's a lot more gas in the tank. Preferred horse in the life insurance sector. 13% ROE. Trades at 7.5x earnings. Should have a "3" handle on it. Yield is 4.2%.

BUY

Likes the chart and lifecos a lot. There's been a downtrend for 2018 and part of 2019, but we're now in an uptrend, at least rangebound. He expects yields to move higher in the future and that will lift all lifeco stocks. Meanwhile, collect the dividend.

Showing 346 to 360 of 2,284 entries

Most Recent Experts

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Manulife Financial (MFC.TO)